RedHill Biopharma (RDHL) Posts Smaller Q1 Loss

RedHill Biopharma (NASDAQ: RDHL) reported Q1 EPS of ($0.03), $0.20 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $18.2 million versus the consensus estimate of $24.3 million.

For earnings history and earnings-related data on RedHill Biopharma (RDHL) click here.

You May Also Be Interested In

• Sprinklr (CXM) Tops Q2 EPS by 1c, Offers Guidance
• RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring’s Rebyota® and Clenpiq®
• Ollie's Bargain Outlet (OLLI) Tops Q2 EPS by 28c, Offers Guidance